We report a 90-year-old 
Introduction

While the number of lung cancer patients within the elderly population is increasing, elderly individuals have limited treatment options due to their generally diminished
. However, the nodule was located close to the right inferior lobar bronchus, and there were no direct findings in the airway. EBUS-TBNA was performed for diagnosis and staging of the lung tumor. Convex probe endobronchial ultrasonography equipped with a 7. 5 
-MHz linear probe on its tip (BF-UC260F-OL8; Olympus Ltd., Tokyo, Japan) and a dedi-
F i g u r e 1 . ( A) Ch e s t CT s h o wi n g a t u mo r s h a d o w ( a r r o w) i n t h e r i g h t l o we r l o b e a d j a c e n t t o t h e r i g h t b a s a l l o b a r b r o n c h u s , a s we l l a s ( B ) s u b c a r i n a l l y mp h a d e n o p a t h y ( # 7 , a r r o w) . ( C) E n d o b r o n c h i a l u l t r a s o u n d ( E B US ) ( a r r o w) wa s p e r f o r me d f o r b o t h t h e s u b c a r i n a l l y mp h n o d e a n d t h e p r i ma r y l u n g t u mo r . ( D) Hi s t o l o g i c a l f i n d i n g s r e v e a l e d a d e n o c a r c i n o ma ( He ma t o x y l i n a n d E o s i n s t a i n i n g × 1 0 0 ) . ( E ) De t e c t i o n o f a n E GF R e x o n 2 1 p o i n t mu t a t i o n ( L 8 5 8 R) b y d i r e c t s e q u e n c i n g ( a r r o w) . ( F ) T wo we e k s a f t e r a d mi n i s t r a t i o n o f g e f i t i n i b , t h e t u mo r d e c r e a s e d i n s i z e ( a r r o w) . I t wa s j u d g e d a s p a r t i a l r e s p o n s e ( P R) a c c o r d i n g t o t h e Re s p o n s e E v a l u a t i o n Cr i t e r i a i n S o l i d T u mo r s ( RE CI S T ) c r i t e r i a ( 2 ) .
cated 22-gauge needle (NA-201SX-4022; Olympus Ltd) were used for EBUS-TBNA.
First, we punctured a subcarinal lymph node (#7), and then we punctured the primary tumor from the basal bronchus of the right lung (Fig. 1C) . Adenocarcinoma was revealed in both the subcarinal lymph node and the primary tumor (Fig. 1D) (Fig. 1E) .
We discussed different treatment options with the patient and her family. She finally selected gefitinib treatment; hence, gefitinib was administrated as first-line therapy. Two weeks after gefitinib administration, the tumor decreased in size and bloody sputum disappeared (Fig. 1F) 
. This was judged as a partial response (PR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria (2
